Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309452 · ClinicalTrials.gov registry record · NA
Specialized Treatment Early in Psychosis (STEP)
A NA study of Schizophrenia and Disorders With Psychotic Features, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00309452: Completed NA study of Schizophrenia and Disorders With Psychotic Features, sponsored by Yale University.
NCT00309452 is a NA study of Schizophrenia and Disorders With Psychotic Features that has completed, run by Yale University. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00309452, a NA study of Schizophrenia and Disorders With Psychotic Features, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive remediation
- BEHAVIORAL MFG
- BEHAVIORAL Cognitive Behavioral Group Therapy
- DRUG Medications
- BEHAVIORAL Assertive case management
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-08 |
| Phase | NA |
What the finished NCT00309452 record still lists
NCT00309452 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Schizophrenia and Disorders With Psychotic Features appearing as the primary indexed condition, and to 5 interventions - of which Cognitive remediation is the first listed.
NCT00309452 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00309452 about?
NCT00309452 is a clinical study titled "Specialized Treatment Early in Psychosis (STEP)". The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.
What is the current status of trial NCT00309452?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2006-03. Estimated completion is 2013-08.
What conditions does trial NCT00309452 study?
This clinical trial studies the following conditions: Schizophrenia and Disorders With Psychotic Features.
What interventions are being tested in trial NCT00309452?
The interventions under investigation include: Cognitive remediation (BEHAVIORAL), MFG (BEHAVIORAL), Cognitive Behavioral Group Therapy (BEHAVIORAL), Medications (DRUG), Assertive case management (BEHAVIORAL).
Who is sponsoring clinical trial NCT00309452?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00309452 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00309452's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia